Effects of testosterone on fat cell lipolysis. Species differences and possible role in polycystic ovarian syndrome

被引:70
作者
Arner, P [1 ]
机构
[1] Karolinska Inst, Dept Med, Stockholm, Sweden
[2] Karolinska Univ Hosp, Karolinska Inst, Dept Med, SE-14186 Stockholm, Sweden
关键词
fat cell; catecholamines; insulin; obesity; PCOS;
D O I
10.1016/j.biochi.2004.11.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Testosterone is a potent regulator of lipolysis by influencing catecholamine signal transduction in fat cells. Major species differences exist as regards the testosterone effect. In rodents testosterone increases beta-adrenergic receptor mediated signals to lipolysis at multiple steps in the lipolytic cascade. The sex hormone also increases alpha(2)-adrenoceptor antilipolytic signalling in hamster which unlike rat express this receptor in their fat cells. In humans the region of adipose tissue is critical. Visceral fat cell lipolysis is not responsive to testosterone but this sex hormone decreases catecholamine-induced lipolysis in subcutaneous fat cells due to inhibition of the expression of beta(2)-adrenoceptors and hormone sensitive lipase. In polycystic ovarian syndrome (PCOS), which is characterized as a hyperandrogenic state, the lipolytic effect of catecholamine is decreased in subcutaneous adipocytes due to low content of beta(2)-adrenoceptors and hormone sensitive lipase. It is possible that the increased testosterone levels are responsible for these abnormalities in catecholamine signal transduction in subcutaneous fat cells of PCOS women. However, in visceral fat cells of PCOS women catecholamine-induced lipolysis is enhanced which cannot be explained by testosterone. (c) 2004 Elsevier SAS. All rights reserved.
引用
收藏
页码:39 / 43
页数:5
相关论文
共 38 条
[1]   The regulation of HSL and LPL expression by DHT and flutamide in human subcutaneous adipose tissue [J].
Anderson, LA ;
McTernan, PG ;
Harte, AL ;
Barnett, AH ;
Kumar, S .
DIABETES OBESITY & METABOLISM, 2002, 4 (03) :209-213
[2]   Not all fat is alike [J].
Arner, P .
LANCET, 1998, 351 (9112) :1301-1302
[3]   The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones [J].
Arner, P .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2003, 14 (03) :137-145
[5]  
BOULOUMIE A, 1994, AM J PHYSIOL, V267, P926
[6]   Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk [J].
Carr, MC ;
Brunzell, JD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) :2601-2607
[7]   Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity [J].
Ciaraldi, TP ;
Morales, AJ ;
Hickman, MG ;
OdomFord, R ;
Olefsky, JM ;
Yen, SSC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (05) :1421-1425
[8]   CELLULAR MECHANISMS OF INSULIN RESISTANCE IN POLYCYSTIC OVARIAN SYNDROME [J].
CIARALDI, TP ;
ELROEIY, A ;
MADAR, Z ;
REICHART, D ;
OLEFSKY, JM ;
YEN, SSC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (02) :577-583
[9]   The metabolic syndrome: A crossroad for genotype-phenotype associations in atherosclerosis [J].
Corella D. ;
Ordovas J.M. .
Current Atherosclerosis Reports, 2004, 6 (3) :186-196
[10]   The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone [J].
De Pergola, G .
INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (Suppl 2) :S59-S63